Do analysts rate MYNZ or FRMM?

Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 86.92%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts plainly believe Forum Markets is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is MYNZ or FRMM more profitable?

Mainz Biomed's return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Forum Markets N/A -242.09% -135.46%

Do analysts rate HRTX or MYNZ?

Heron Therapeutics presently has a consensus target price of $2.50, indicating a potential upside of 524.84%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer RNTX or MYNZ?

Rein Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 630.77%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rein Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is RNTX or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat Rein Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A -510.35% -68.14% Mainz Biomed N/A N/A N/A

Is AARD or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -61.71% -56.29% Mainz Biomed N/A N/A N/A

Do analysts prefer MYNZ or HYFT?

MindWalk has a consensus price target of $5.00, indicating a potential upside of 220.51%. Given MindWalk's stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable earnings & valuation, MYNZ or HYFT?

Mainz Biomed has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 23.75 -$21.65M -$65.60 N/A MindWalk $17.59M 4.09 -$21.69M -$0.20 N/A

Mainz Biomed (MYNZ) Competitors

$1.73 -0.17 (-8.95%)

As of 06/12/2026

Compare

MYNZ vs. FRMM, HRTX, RNTX, AARD, and HYFT

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include Forum Markets (FRMM), Heron Therapeutics (HRTX), Rein Therapeutics (RNTX), Aardvark Therapeutics (AARD), and MindWalk (HYFT). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to Forum Markets?

Mainz Biomed (NASDAQ:MYNZ) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Mainz Biomed's return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Forum Markets	N/A	-242.09%	-135.46%

In the previous week, Forum Markets had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Forum Markets and 0 mentions for Mainz Biomed. Forum Markets' average media sentiment score of 0.94 beat Mainz Biomed's score of 0.00 indicating that Forum Markets is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Forum Markets	Positive

Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 86.92%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts plainly believe Forum Markets is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

4.1% of Forum Markets shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 15.1% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mainz Biomed has higher earnings, but lower revenue than Forum Markets. Forum Markets is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A
Forum Markets	$6.55M	11.88	-$450.52M	-$36.07	N/A

Summary

Forum Markets beats Mainz Biomed on 10 of the 16 factors compared between the two stocks.

How does Mainz Biomed compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

80.0% of Heron Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mainz Biomed has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Mainz Biomed's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Mainz Biomed	N/A	N/A	N/A

Heron Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Heron Therapeutics had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Heron Therapeutics and 0 mentions for Mainz Biomed. Heron Therapeutics' average media sentiment score of 0.94 beat Mainz Biomed's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Mainz Biomed	Neutral

Heron Therapeutics presently has a consensus target price of $2.50, indicating a potential upside of 524.84%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Heron Therapeutics has higher revenue and earnings than Mainz Biomed. Heron Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.49	-$20.19M	-$0.18	N/A
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A

Summary

Heron Therapeutics beats Mainz Biomed on 10 of the 16 factors compared between the two stocks.

How does Mainz Biomed compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Rein Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 630.77%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rein Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Rein Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Mainz Biomed	N/A	N/A	N/A

In the previous week, Rein Therapeutics had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Rein Therapeutics and 0 mentions for Mainz Biomed. Rein Therapeutics' average media sentiment score of 0.63 beat Mainz Biomed's score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rein Therapeutics	Positive
Mainz Biomed	Neutral

Mainz Biomed has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A

90.9% of Rein Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Rein Therapeutics beats Mainz Biomed on 8 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Mainz Biomed has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A

Aardvark Therapeutics has a beta of 4.47, suggesting that its share price is 347% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Mainz Biomed	N/A	N/A	N/A

In the previous week, Aardvark Therapeutics had 6 more articles in the media than Mainz Biomed. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 0 mentions for Mainz Biomed. Aardvark Therapeutics' average media sentiment score of 0.72 beat Mainz Biomed's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Positive
Mainz Biomed	Neutral

Aardvark Therapeutics presently has a consensus target price of $19.70, indicating a potential upside of 405.13%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Aardvark Therapeutics beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does Mainz Biomed compare to MindWalk?

Mainz Biomed (NASDAQ:MYNZ) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Mainz Biomed has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A
MindWalk	$17.59M	4.09	-$21.69M	-$0.20	N/A

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

6.7% of MindWalk shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, MindWalk had 6 more articles in the media than Mainz Biomed. MarketBeat recorded 6 mentions for MindWalk and 0 mentions for Mainz Biomed. MindWalk's average media sentiment score of 0.61 beat Mainz Biomed's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
MindWalk	Positive

MindWalk has a consensus price target of $5.00, indicating a potential upside of 220.51%. Given MindWalk's stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Mainz Biomed has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Mainz Biomed's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
MindWalk	-66.79%	-69.37%	-39.74%

Summary

MindWalk beats Mainz Biomed on 10 of the 17 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.67M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.03	20.00	24.00	24.42
Price / Sales	23.75	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.66	8.32	10.55	6.82
Net Income	-$21.65M	$23.94M	$3.57B	$337.56M
7 Day Performance	-21.36%	1.84%	0.59%	1.16%
1 Month Performance	-42.33%	-0.04%	1.55%	3.16%
1 Year Performance	-5.46%	44.82%	25.41%	30.60%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	N/A	$1.73 -8.9%	N/A	-5.5%	$15.67M	$659.94K	N/A	30	High Trading Volume
FRMM Forum Markets	2.5485 of 5 stars	$5.47 +2.9%	$10.00 +83.0%	N/A	$79.39M	$6.55M	N/A	7	Analyst Upgrade
HRTX Heron Therapeutics	1.7895 of 5 stars	$0.42 -7.8%	$2.50 +498.1%	-79.3%	$78.93M	$150.71M	N/A	300
RNTX Rein Therapeutics	3.8289 of 5 stars	$0.92 -3.2%	$7.00 +662.5%	-49.0%	$78.70M	N/A	N/A	9	Gap Down
AARD Aardvark Therapeutics	4.2249 of 5 stars	$3.54 -1.4%	$19.70 +456.5%	-63.7%	$76.81M	N/A	N/A	18	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. FRMM, HRTX, RNTX, AARD, and HYFT

How does Mainz Biomed compare to Forum Markets?

Summary

How does Mainz Biomed compare to Heron Therapeutics?

Summary

How does Mainz Biomed compare to Rein Therapeutics?

Summary

How does Mainz Biomed compare to Aardvark Therapeutics?

Summary

How does Mainz Biomed compare to MindWalk?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. FRMM, HRTX, RNTX, AARD, and HYFT

How does Mainz Biomed compare to Forum Markets?

Is MYNZ or FRMM more profitable?

Does the media refer more to MYNZ or FRMM?

Which has more risk & volatility, MYNZ or FRMM?

Do analysts rate MYNZ or FRMM?

Do institutionals & insiders hold more shares of MYNZ or FRMM?

Which has stronger valuation & earnings, MYNZ or FRMM?

Summary

How does Mainz Biomed compare to Heron Therapeutics?

Do institutionals and insiders believe in HRTX or MYNZ?

Is HRTX or MYNZ more profitable?

Which has more volatility & risk, HRTX or MYNZ?

Does the media favor HRTX or MYNZ?

Do analysts rate HRTX or MYNZ?

Which has preferable valuation and earnings, HRTX or MYNZ?

Summary

How does Mainz Biomed compare to Rein Therapeutics?

Do analysts prefer RNTX or MYNZ?

Which has more volatility & risk, RNTX or MYNZ?

Is RNTX or MYNZ more profitable?

Does the media favor RNTX or MYNZ?

Which has preferable valuation & earnings, RNTX or MYNZ?

Do insiders and institutionals hold more shares of RNTX or MYNZ?

Summary

How does Mainz Biomed compare to Aardvark Therapeutics?

Which has preferable earnings and valuation, AARD or MYNZ?

Which has more volatility & risk, AARD or MYNZ?

Is AARD or MYNZ more profitable?

Does the media prefer AARD or MYNZ?

Do analysts recommend AARD or MYNZ?

Summary

How does Mainz Biomed compare to MindWalk?

Which has preferable earnings & valuation, MYNZ or HYFT?

Which has more volatility and risk, MYNZ or HYFT?

Do institutionals and insiders believe in MYNZ or HYFT?

Does the media refer more to MYNZ or HYFT?

Do analysts prefer MYNZ or HYFT?

Is MYNZ or HYFT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools